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Abstract
Chronic hepatitis B virus (HBV) infection is a global public health challenge on the same scale as 
tuberculosis, HIV, and malaria. The International Coalition to Eliminate HBV (ICE-HBV) is a 
coalition of experts dedicated to accelerating the discovery of a cure for chronic hepatitis B. 
Following extensive consultation with more than 50 scientists from across the globe, as well as key 
stakeholders including people affected by HBV, we have identified gaps in our current knowledge 
and new strategies and tools that are required to achieve HBV cure. We believe that research must 
focus on the discovery of interventional strategies that will permanently reduce the number of 
productively infected cells or permanently silence the covalently closed circular DNA in those 
cells, and that will stimulate HBV-specific host immune responses which mimic spontaneous 
resolution of HBV infection. There is also a pressing need for the establishment of repositories of 
standardised HBV reagents and protocols that can be accessed by all HBV researchers throughout 
the world. The HBV cure research agenda outlined in this position paper will contribute markedly 
to the goal of eliminating HBV infection worldwide.
Introduction
Hepatitis B virus (HBV) is a major global public health threat with over 257 million people 
worldwide chronically infected; over 887 000 deaths are caused by the virus every year.1 
Chronic hepatitis B causes almost 40% of cases of hepatocellular carcinoma, which is the 
second leading cause of cancer-related mortality worldwide.2 The current prophylactic 
vaccine has no effect on established chronic infection. Available treatments suppress viral 
replication but they are not curative, largely due to the persistence of the viral covalently 
closed circular DNA (cccDNA) transcriptional template in infected hepatocytes and the 
failure of chronically infected patients to mount an immune response that is sufficiently 
robust, functional, and sustained to clear the infection.3 Thus, in most cases, treatment must 
continue for life. However, even successfully virally suppressed patients may still develop 
liver cancer, especially if their livers are cirrhotic.4
Despite the huge human and economic toll of chronic hepatitis B,2 HBV research remains 
largely underfunded,5 to the point of recently being compared to a neglected tropical 
disease.6 Given recent scientific progress and the momentum created by hepatitis C virus 
(HCV) cure discoveries, together with the immense public health impact of chronic hepatitis 
B, we believe that governments, foundations, industry, and academic research institutions 
throughout the world can and should join forces and work together to accelerate HBV cure 
research.
The International Coalition to Eliminate HBV (ICE-HBV) is an international, independent, 
research-based forum created in 2016 to accelerate HBV cure research. ICE-HBV aims to 
coordinate, promote, and foster collaborative partnerships working towards an HBV cure 
and the alleviation of suffering for all individuals living with chronic hepatitis B.7 Following 
an inclusive nomination process, ICE-HBV formed international multidisciplinary scientific 
working groups consisting of leaders in HBV virology, immunology, technology, and 
clinical research, who have collaborated to identify current strengths in the HBV field that 
can be built upon, as well as knowledge gaps that must be addressed to achieve cure. The 
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strategy presented here is the result of a 2 year-long process, involving over 50 scientists 
from five continents with input from key HBV research stakeholders from 21 countries. 
Through this process, we propose a strategic and collaborative HBV research agenda to 
advance the discovery of a safe, affordable, scalable, and effective chronic hepatitis B cure, 
accessible to all within the foreseeable future.
The HBV lifecycle
The HBV replication cycle is outlined in figure 1. There are still many gaps in our 
understanding of the HBV replication cycle that are major barriers to HBV cure research, 
particularly concerning the biogenesis, homoeostasis, and turnover of the cccDNA reservoir. 
However, recent technological advances, such as the discovery of the NTCP HBV entry 
receptor,8 have led to the development of additional cell culture models that, together with 
other available systems (primary human hepatocytes, HepaRG cells, transient transfection 
systems, stably transformed cell lines, hepatocyte-like cells derived from induced pluripotent 
stem cells) and the use of humanised mice, permit interrogation of the complete HBV 
replication cycle. These developments make it feasible to systematically study the 
mechanisms that control the biogenesis, homoeostasis, and decay of the cccDNA 
transcriptional template, and to use that information to identify vulnerabililites in cccDNA 
machinery that could in turn be exploited to eradicate HBV from infected cells.
Chronic hepatitis B and resolution of infection
In the absence of vaccination, over 90% of individuals infected in infancy will progress from 
acute hepatitis to lifelong chronic infection. By contrast, over 90% of people infected in 
adulthood will resolve the infection, due to robust immune responses that eliminate infected 
cells and produce neutralising antibodies that provide lifelong protection. Once chronic 
infection is established, patients are exposed to significant risk of liver disease including 
chronic hepatitis, cirrhosis, and hepatocellular carcinoma. The natural history of chronic 
HBV infection usually consists of up to five stages,13 which differ in the level of viral 
replication, viral antigen expression, and inflammatory activity in the liver.
Although only approximately 1% of chronically infected individuals per year mount an 
effective immune response to control chronic hepatitis B infection, spontaneous resolution 
of acute and chronic hepatitis B proves that immune control of HBV infection is possible. 
However, the clinical resolution of a chronic infection or of acute hepatitis does not mean 
complete eradication of the virus, as small numbers of cccDNA-positive infected 
hepatocytes can persist in these individuals14–16 and may be the source of viral reactivation 
during immune suppression.17 Thus, an unknown number of the two billion people alive 
today who have resolved previous HBV infection maintain a viral cccDNA reservoir in their 
liver, as demonstrated by the emergence of chronic hepatitis B infection in people who were 
infected and initially recovered from HBV infection but in whom the virus reactivated when 
exposed to therapies inducing immune suppression for other medical conditions.17 We 
believe that improving our understanding of the biogenesis and homoeostasis of HBV 
cccDNA is urgently required if we are to develop strategies to eliminate it from infected 
cells, or control its expression.
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Immunise, test, and treat
Before chronic hepatitis B can be cured, we need to know who is infected and their stage of 
disease. Only 10% of the estimated number of individuals living with HBV infection in 2016 
knew of their status, and of those diagnosed, only 5% of those who were eligible for 
treatment actually received treatment.18 WHO aims to eliminate viral hepatitis as a major 
public health threat by 2030,19 and while increasing preventive vaccine coverage is the main 
cornerstone of this global effort to achieve elimination, WHO also proposes an increase of 
the proportion of eligible individuals treated for chronic hepatitis B to 80%. This will require 
a concomitant increase in global HBV testing worldwide. Priority should be given to 
development of rapid point-of-care tests for use in countries of low and middle income, 
where HBV is highly endemic. Since there are already effective treatments that have a 
marked effect on HBV replication and liver disease, increased efforts must be made to 
improve access globally. Large-scale accessible diagnosis and treatment facilities in 
countries of low and middle income should be established to reduce mortality and ensure 
HBV cure preparedness,20 while also investing in HBV cure strategies, which could allow 
important cost-savings for health systems in the long run.21
Current treatments are limited to nucleos(t)ide analogues, which are direct-acting antivirals 
that block DNA synthesis,22 and interferon-α. Interferon-α produces its antiviral effects by 
several mechanisms, including direct suppression of RNA and protein production in infected 
cells23 and inhibition of HBV DNA replication by blocking nudeocapsid assembly,24 in 
addition to immunomodulatory activity, such as the activation of NK cells and T cells that 
can target HBV-infected cells.25–27 Thus, in a small subset of patients, interferon-α 
treatment can result in cure. By contrast, nucleos(t)ide analogues only inhibit HBV genome 
replication; they have minimal effects on the immune response or the cccDNA 
minichromosome reservoir, and are not curative.
Monitoring and prevention of cancer
Current antiviral therapies reduce but do not eliminate the risk of liver cancer. As curative 
therapies are developed, it will be important to monitor patients for progression to liver 
cancer, even if they have been cured of chronic HBV infection. This is particularly important 
for patients with cirrhosis, who are generally thought to be most at risk for development of 
liver cancer; however, certain HBV subgenotypes, such as African A1 and Alaskan Fib are 
strongly associated with liver cancer in the absence of underlying cirrhosis.28 While studies 
have identified HBV-related factors associated with increased likelihood of progressing to 
liver cancer (high viral load, HBeAg positivity, genotype C, and failure to clear HBsAg 
before the age of 5029,30), there are currently no predictive biomarkers that accurately 
predict the onset of cancer in the setting of HBV infection. Even though the cure of infection 
is likely to reduce the likelihood of developing liver cancer, the direct impact of integrated 
HBV DNA and the viral proteins (eg, HBsAg and HBx) expressed from integrants on 
cellular gene expression and hepatocyte homoeostasis will need to be carefully considered. 
Accordingly, new markers that predict the likelihood of progression of chronic HBV 
infection, with or without cirrhosis, to liver cancer should be developed.
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Definitions of HBV cure
Discussions about HBV cure are complicated by the need to consider curing both the 
infection and the associated liver disease (panel 1). Previous discussions of HBV cure have 
focused mainly on curing the infection, either by eliminating the virus (ie, complete cure), or 
by controlling the virus or inducing host immune responses to eliminate the infection and 
prevent viral spread (ie, functional cure).7–31,32 A recent joint American Association for the 
Study of Liver Diseases-European Association for the Study of the Liver workshop on HBV 
treatment endpoints further defined complete cure as a complete sterilising cure with 
undetectable HBsAg in serum and eradication of HBV DNA including intrahepatic cccDNA 
and integrated HBV DNA.31 Functional cure was defined as sustained, undetectable HBsAg 
and HBV DNA in serum with or without seroconversion to hepatitis B surface antibody 
(anti-HBs), with the persistence of low amounts of intrahepatic cccDNA and HBV DNA 
intergration.31 A third definition was also proposed (partial cure), defined as detectable 
HBsAg but persistently undetectable HBV DNA in serum after completion of a finite course 
of treatment.31 Since it is currently not possible to eradicate the HBV cccDNA 
minichromosome reservoir or integrated HBV DNA from every infected cell, functional cure 
is more likely to be achievable, at least initially. Indeed, a complete sterilising cure is yet to 
be observed naturally in any individuals living with chronic HBV, nor in individuals who 
have recovered from transient acute HBV infection, and seems unlikely to be achievable 
therapeutically, at least in the short term.
It is questionable whether current therapies could replicate spontaneous recovery from acute 
hepatitis B. Studies in chimpanzees showed that in resolution of acute HBV infection, 
almost all infected hepatocytes are eliminated by the CD8+ T-cell response,33 although HBV 
is also cleared by non-cytopathic mechanisms.34 A very small proportion of infected cells 
remain, with infection of new cells prevented by anti-HBs.35 Such resolution and control of 
HBV infection has occurred naturally in millions of individuals with acute infection. 
Although this is rarely achieved by currently available treatments in individuals with chronic 
hepatitis B, it does occur and indicates that HBV need not be totally eradicated to achieve 
lifelong viral control by a sustained cellular and humoral immune response. With this 
background, we believe that the ideal aim of a curative therapeutic regimen for chronic HBV 
infection should be to induce resolution similar to that observed in acute or chronic hepatitis 
B resolvers, as long as this can be done in a safe manner.
The clinical goal of chronic hepatitis B remission is the resolution of residual liver injury 
including disappearance of inflammation, prevention of fibrosis progression, reversal of 
fibrosis and cirrhosis, prevention of liver failure, and reduction of the risk of developing 
hepatocellular carcinoma,31 following completion of a finite course of treatment. Great 
progress has been made in this regard, with the latest generation nucleos(t)ide analogues 
demonstrating reversal of fibrosis and reduced likelihood of progression to hepatocellular 
carcinoma in many, but not all, patients.36,37 However, treatment is long term and a high 
priority of curative treatments is that treatment be finite, while still meeting the goals of 
disease remission. Remission in early chronic hepatitis B, where no fibrosis is yet present, is 
analogous to a person who clears acute HBV infection, but retains HBV cccDNA in some of 
their hepatocytes—there is no evidence of ongoing liver disease, but the viral reservoir is 
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still present, albeit at very low levels tightly constrained by the humoral and cellular immune 
responses. Although the remission of liver disease in chronic hepatitis B does not preclude 
potential reactivation of disease, it largely meets the societal goal of cure, namely the 
prevention of adverse outcomes, restoration of health, prolongation of life expectancy after 
cessation of therapy, elimination of transmission risks, and removal of stigma associated 
with having a chronic communicable disease,38 all of which should be the guiding principles 
in the ultimate adoption of a definition.
As a result of academic and industrial efforts to identify viral targets for drug discovery, a 
number of drugs are being evaluated in preclinical models or are in the first phases of 
clinical development (figure 2).40 These include drugs interfering with viral entry, drugs or 
other methods targeting cccDNA or viral RNA, novel polymerase or ribonuclease H 
inhibitors, core protein allosteric modulators and capsid assembly modulators, drugs 
interfering with HBx function, drugs targeting viral and HBsAg egress, or agents affecting 
the viral proteome (eg, small interfering RNA and RNA destabilisers). Some of these 
compounds appear promising, with marked reductions in HBV viral load or circulating 
HBsAg, or both, and the emergence of anti-HBs, but to date none seem to be capable of 
curing HBV infection on their own.7,32 None of these approaches directly target the HBV 
cccDNA reservoir, but it will be important to evaluate these approaches in combination, to 
determine their effectiveness in the kinetics of cccDNA clearance or in their capacity to 
improve the restoration of antiviral immune responses. Earlier attempts to boost innate 
immunity and adaptive immune responses did not lead to improved cure rates, as defined by 
HBsAg loss. It is therefore critical to design drug combinations with the aim that they are 
curative. To this end, following extensive discussion among the ICE-HBV working groups, 
we have prioritised the research necessary to achieve HBV cure and the tools that will be 
required to achieve this goal. These are described in the context of key concepts that should 
be addressed to eliminate HBV from infected cells and induce effective immune control.
We believe that research efforts should focus on reducing the number of cccDNA molecules 
per cell and the number of cccDNA-containing cells, and on inducing HBV-specific immune 
responses to achieve what the host is capable of achieving during the resolution of infection, 
namely profound reduction of the number of infected cells and induction of HBV-specific 
immune responses that prevent viral spread from those that remain infected. Such 
approaches need to be done in a manner that is safe, durable, and affordable. Increased 
efforts will be needed to improve our understanding of the biogenesis, homoeostasis, 
transcriptional regulation, and decay of the viral cccDNA reservoir,9 together with a deeper 
understanding of factors required to induce host immune responses that control or eliminate 
HBV infection in individuals with chronic hepatitis B. However, it is also important that 
research continues to gain knowledge about many other aspects of the HBV replication 
cycle, including viral entry and uncoating, mechanisms regulating cccDNA activity, gene 
expression including mRNA translation and splicing, and packaging of pgRNA and its 
reverse transcription forming the main replication complexes, subviral particle formation, 
and viral egress.
To achieve our goal of HBV cure, ICE-HBV proposes two strategies, namely curing of HBV 
infection without killing infected cells and inducing immune control to safely eliminate 
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infected cells. Each of these approaches will need to be underpinned by coordinated clinical 
studies to advance HBV cure. Detailed descriptions of each of these strategies, together with 
the clinical approaches necessary to advance HBV cure, are presented below.
Strategy 1: curing HBV infection without killing infected cells
More than 50 years have elapsed since the discovery of HBsAg.41 The discovery of the HBV 
entry receptor NTCP in 20128 revolutionised our ability to study in vitro the HBV 
replication cycle from infection to egress, and the development of new animal models that 
permit studies of immunopathogenesis42–44 and preclinical antiviral evaluation. However, 
these models still have considerable limitations, and important gaps in our understanding of 
the HBV replication cycle and the host immune response must be addressed to expand the 
exploitable vulnerabilities in the replication cycle that can be targeted therapeutically to cure 
the infection.
Targeting the cccDNA minichromosome reservoir
The HBV cccDNA minichrommosome reservoir in the nucleus of infected hepatocytes is the 
single most important barrier to curing chronic HBV infection. We suggest that research 
directed towards elimination of cccDNA or permanently silencing cccDNA transcription 
should be prioritised.
cccDNA elimination will be the most direct and efficient strategy to cure chronic HBV 
infection. Current antiviral drugs do not eliminate cccDNA, even after prolonged treatment 
either in patients or experimental cell culture or animal models. The observation that 
cytokine administration, including interferon-α, may induce APOBEC-dependent 
deamination of viral DNA45–47 has led to considerable discussion of whether this could lead 
to a substantial decrease of cccDNA in infected hepatocytes.48–50 Approaches that directly 
target cccDNA (eg, CRISPR/Cas950 or other gene editing methodologies51) have shown 
promising results in laboratory studies, but issues including hepatocellular delivery, off-
target effects, and the likelihood that they will also cleave chromosomally integrated HBV 
DNA and thus trigger unpredictable consequences of chromosomal DNA recombination will 
need to be carefully considered. Because of these potential dangers and difficulties, 
approaches that target viral or host proteins that are critical for cccDNA formation, stability, 
and expression (eg, HBx) must be further explored. An intense and coordinated effort will be 
required to discover the fundamental biochemical, cellular, and physiological basis of 
cccDNA production, maintenance, and turnover, about which very little is known. Now that 
it is possible to study the complete HBV replication cycle, we believe these studies are 
imperative because cccDNA elimination is the only strategy that has the potential to 
definitively produce a safe, durable cure of HBV infection.
Since cccDNA is not completely eradicated during spontaneous or treatment-induced 
resolution of acute or chronic infection,52 it is unlikely that total eradication of cccDNA will 
be achievable pharmacologically. Transcriptional silencing of the residual pool of cccDNA 
remaining after most of the cccDNA is eliminated or antibody-mediated prevention of virus 
spread from the remaining infected cells (or both) will probably also be necessary. While 
modification of epigenetic control of cccDNA by general epigenetic modifiers would 
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probably be too risky in terms of potential adverse events on cell homoeostasis, other 
strategies targeting viral factors involved in the regulation of cccDNA transcriptional activity 
should be pursued. Transcriptional control of cccDNA expression may be achieved by 
targeting the HBx protein, which is critical for cccDNA expression or stability.53–56 Greater 
insight into the role of HBx, HBc,57 and other viral proteins in the control of cccDNA 
homoeostasis is thus mandatory. The Smc5/6 complex is a host restriction factor that, in the 
absence of HBx protein, represses cccDNA expression.58–60 It has recently emerged that 
HBx promotes cccDNA transcription by hijacking cellular DDB1-containing E3 ubiquitin 
ligase to target the Smc5/6 complex for degradation.58 Therefore, therapeutic approaches 
targeting the HBx-DDB1 binding interaction are also worthy of investigation. Post-
transcriptional control of cccDNA or integrated HBV DNA expression can be achieved 
using RNA interference; this is currently being pursued, with promising results.61,62 The 
overlapping nature of the HBV genome suggests that RNA interference should impede 
expression of all HBV transcripts, and it has recently been shown that truncated forms of 
transcripts derived from integrated viral DNA can also be targeted.61 There is also a pressing 
need for the development of in-situ, single-cell, singlemolecule, live-cell assays, to visualise 
the localisation and trafficking of cccDNA,63,64 and cccDNA-dependent surrogate reporter 
cell systems for high throughput screening of cccDNA inhibitors.65–67
New models are required
Although it is now possible to interrogate the complete HBV replication cycle in cell 
culture, the current models still have some limitations. For example, most studies to date 
have been limited to HBV genotype D, the only genotype for which stably transformed cell 
lines are readily available to produce HBV at sufficient multiplicity of infection for 
downstream experiments. Additionally, the transformed nature of hepatoma cells means that 
they do not fully reflect primary liver cells. Primary human hepatocytes—the natural target 
cells for HBV infection in vivo—are available and support the complete HBV replication 
cycle, and are presumably more physiologically relevant to hepatocytes in the liver. 
However, their use has limitations: they require polyethylene glycol, dimethylsulfoxide, and 
high amounts of input virus for infection; they are expensive; they have a limited 
polarisation and life-span in vitro; and batch-to-batch variations affect infection efficiency 
and responses to infection.68
In-vitro models that would eliminate the need for polyethylene glycol and provide 
consistency and uniformity of infection from lab to lab over time are needed to accelerate 
the discovery process and to confirm the reproducibility of promising new data. Systems that 
have the chance of satisfying these criteria include human hepatocyte-like cells 
differentiated in vitro from embryonic stem cells or induced pluripotent stem cells69–71 and 
three-dimensional microfluidic liver cultures, which permit analysis of the complete HBV 
replication cycle.72 However, all available HBV infection systems only support limited viral 
spreading in the cultures. Culture systems that support robust amplification of HBV are 
needed.
Furthermore, none of the current animal models for HBV infection is optimal,68 especially 
in the context of HBV cure research. Despite the existence of immune-deficient humanised 
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mouse models permitting studies of HBV infection and spreading in vivo, as well as to 
evaluate the efficacy of direct antiviral compounds in HBV-infected primary human 
hepatocytes, immunocompetent mouse models that are susceptible to HBV infection are 
only now starting to become available. Humanised mouse models will also enable studies on 
long-term effects of drugs on cccDNA maintenance and loss in non-dividing versus dividing 
hepatocytes.73 Further development of double humanised mouse models (liver and immune 
system) will permit studies of immune-mediated clearance.42,43,74 Breaching the current 
intracellular block to HBV infection and cccDNA formation in mouse hepatocytes75 would 
generate a small animal model, enabling analysis of the immune response to HBV that may 
facilitate immune-mediated cccDNA elimination and control, similar to clearance of acute 
HBV infection. Thus, we believe that the further development of humanised mouse models 
amenable to HBV infection should receive high priority because of their great potential to 
enable studies of mechanisms regulating cccDNA metabolism and clearance.
With the loss of the chimpanzee model of HBV infection, the only primate model available 
to the HBV research community is the tree shrew (Tupaia belangeri chinensis).76,77 
Research with this model, however, is severely limited by the absence of a deep portfolio of 
Tupaia-based reagents for virological and immunological analysis. However, the discovery 
that HBV uses NTCP as its receptor raised the possibility of creating a macaque model for 
HBV infection by expressing human NTCP on macaque hepatocytes after infection with 
recombinant adeno-associated virus vectors, leading to HBV infection for at least 6 weeks.78 
If improved, this model has the potential to not only better understand the immunobiology 
and pathogenesis of HBV infection and test immunomodulatory approaches to cure chronic 
HBV infection, but also to study the therapeutic potential of HBV-targeted drugs, including 
those that target cccDNA. A macaque model would benefit immediately from the wealth of 
information and reagents that have been developed during the use of macaques to study 
simian immunodeficiency virus immunobiology and pathogenesis.79 We believe that the 
establishment of a human NTCP transgenic macaque model should be of high priority for 
the HBV cure research community and for international governmental research funding 
agencies interested in or committed to curing chronic HBV infection.
Since all current experimental models have limitations, and differences between HBV and 
HBV-related viruses have emerged, it is likely that observations previously made with HBV-
related viruses require confirmation using HBV and human hepatocytes.80 The research 
priorities and tools required for HBV elimination are shown in panel 2.
Strategy 2: inducing immune control to safely eliminate HBV-infected cells
A complex interplay of innate and adaptive immune responses is essential for viral clearance 
and a failure of these responses can result in liver pathogenesis. CD8+ T cells are the main 
effector cells that eliminate the virus by cytolytic and non-cytolytic effector functions.33,34 
However, sufficient CD4 T-cell activity and the production of neutralising anti-HBV 
envelope antibodies are required for protective immunity.85 A major effort has been made to 
compare the efficient integrated response resulting in HBV clearance of acute infection to 
the dysregulated response observed in patients with chronic hepatitis B. This knowledge has 
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led to the development of the first generation of immune-based therapies and a second 
generation of therapeutic vaccines entering phase 1 and 2 clinical trials.
Current immunotherapies for chronic HBV infection
Key points of immune regulation that can be targeted for therapy have been identified in 
studies done in animal models and HBV-infected patients. Injection of ligands targeting 
Toll-like receptors (TLRs) or RIG-I leads to suppression of viral replication in HBV mouse 
models.86,87 This observation has led to the development of drugs targeting TLR-7,88 
TLR-8, and RIG-I89 for use in chronically HBV-infected patients. Numerous experiments 
have revealed that blocking inhibitory receptors can enhance expansion and function of 
HBV-specific T cells, both in vitro90–94 and in vivo.95,96 This has motivated the use of anti-
PD-1/PD-L1 antibodies in phase 1 studies in chronically HBV-infected patients. 
Furthermore, interleukin-12 appears critical to restoring T-cell expansion and function in 
chronic infection.97 This has led to interleukin-12, or adjuvants inducing it, being 
incorporated into the new generation of therapeutic vaccines for chronic HBV.98
That immunological observations have translated to new experimental therapies is 
encouraging. Now, a critical step is to ensure proper immunological evaluation of these 
strategies to improve their efficacy for future generations of immunotherapy. Additionally, 
continued investigation into the dysregulation of antiviral responses in HBV infection is key 
to expand the repertoire of immune-based therapies. Further integration of data is key to 
effective T-cell-based therapies, defining networks of T-cell exhaustion mechanisms and the 
extent to which T-cell functionality can be restored. Since anti-HBs is considered the clinical 
indicator of HBV resolution, we need a better understanding of the role of B cells and 
neutralising antibody response in the natural history of chronic hepatitis B and how they can 
be effectively enhanced. Mounting evidence for organ-specific immunity necessitates 
analysis of the liver environment.99–101 Furthermore, accurate quantification of the number 
of infected hepatocytes in patients with chronic hepatitis B is important to avoid immune-
related toxicity (panel 3). We highlight areas of research that are central to addressing these 
knowledge gaps to improve the application of immune-based therapies.
Methodology to improve ex-vivo analysis of HBV-specific immunity
Compared with chronic infection with HCV, the frequency of virus-specific peripheral blood 
T cells in patients with chronic hepatitis B is 10–100 fold lower,102 and often undetectable 
using standard assays directly ex vivo. Better and more sensitive assays or novel strategies 
for ex-vivo measurement of HBV-specific immunity in peripheral blood and liver are needed
—eg, to correlate HBV-specific immunity with stage of disease, responses to 
immunotherapy, and antiviral drugs. They are also needed to define biomarkers that best 
identify patients who can safely stop antiviral therapy and reflect intrahepatic immunity in 
the peripheral blood.
Similarly, novel approaches are needed to study the comprehensive phenotypic and 
functional characteristics of the intrahepatic T-cell responses using limited number of cells 
from individual biopsies. These data need to be compared with responses in the blood and 
then applied as immune-based biomarkers that predict or reflect viral control and 
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inflammation. This comparison needs to be done in chronically HBV-infected patients at 
different stages of disease. Additionally, assays that allow the analysis of T cells of different 
epitope specificity need to be further developed to overcome limitations imposed by 
pentamer/tetramer staining that only partially reflect the overall antiviral immune response.
Mechanisms of HBV-mediated T-cell exhaustion and recovery
HBV persistence is associated with CD8+ T-cell exhaustion and (to a lesser extent) with 
viral escape. Persistent exposure to high antigen loads and antigen presentation by 
hepatocytes play a key role in CD8+ T-cell exhaustion.95,103 The expression of inhibitory 
receptors (predominantly PD-1),90,95,96 depletion of amino acids (eg, arginine and 
tryptophan),104 and mitochondrial alterations105 contribute to T-cell dysfunction (figure 3). 
Additionally, lack of CD4+ T-cell helper activity,85,106 immunosuppressive cytokines,107 
regulatory T (Treg) cells,108 granulocytic myeloid-derived suppressor cells,109 and NK 
cells110 also contribute to CD8+ T-cell failure.25,111However, the relative contribution of 
these different mechanisms to T-cell exhaustion are not well characterised and should be 
actively pursued. Also, whether functional T-cell restoration is possible, and if so, how much 
restoration is required for HBV control, is not fully understood. Understanding these aspects 
will refine our targets to restore T-cell functionality and improve immunotherapy.
Comprehensive analysis of the immune responses of patients with active and inactive 
chronic HBV infection (with and without antiviral therapy), patients with resolved HBV 
infection, chronically infected patients with HBsAg loss, and vaccinated healthy individuals 
will help define the level of immune function or reconstitution needed for viral control. 
Recent evidence suggests we need a better understanding of metabolic immune regulation, 
how this relates to overt, detectable inhibitory receptor expression in immune cells, and how 
this is linked to a broader profile of immune dysfunction. To evaluate the efficacy of 
checkpoint blockade, the possibility that differential baseline expression of inhibitory 
molecules and their ligands differ in chronically infected patients versus resolvers should be 
assessed. A better understanding of the relative contribution of inhibitory receptors (eg, 
PD-1, CTLA-4, Tim-3) at different stages of disease is required to determine the patient 
populations that are most likely to benefit from checkpoint blockade therapy.
B cells in the natural history of disease
Anti-HBV antibodies are used as biomarkers for resolution of HBV infection but the 
immunological impact of B cells and antibodies on the natural history and resolution of 
chronic HBV infection, or on seroconversion in chronic HBV infection, have been under-
investigated.112 B cells can produce the immune-suppressive cytokine interleukin-10 but 
their depletion can also result in clinical reactivation in both patients with resolved infection 
and those with chronic hepatitis B.107,113,114 Therefore, fundamental questions related to B-
cell biology, antibody specificity, and neutralising responses need to be addressed so that B 
cells can be incorporated more effectively into new immunotherapeutic approaches.
Assays and reagents need to be developed and optimised for the detection and quantification 
of HBV-specific B cells. ELISPOT assays are needed for accurate and reproducible 
quantification of B cells producing HBV-specific antibodies for research and clinical trial 
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monitoring. Flow cytometry-based reagents are needed to investigate the phenotypic, 
functional, and genetic profile of HBV-specific B cells. Deeper analysis of antibody 
specificity, isotype, and functional responses in different stages of HBV infection should be 
a key area of future research.
Accurately measuring the frequency of infected hepatocytes
The primary safety concern with immunotherapy in chronic HBV infection is the induction 
of fulminant hepatitis. Therefore, it is important to know the actual number of infected 
hepatocytes, the number of hepatocytes expressing viral antigens, and the number of 
hepatocytes that can be destroyed in an individual patient without causing hepatic 
deficiency. HBV integration occurs early in cell culture infection but it is unclear how 
cytolytic versus non-cytolytic mechanisms will target infected hepatocytes (with replicating 
HBV) versus those with integration.61,115 It is imperative to understand the frequency of 
infected and integrated hepatocytes and how hepatocytes are cleared of HBV or HBsAg to 
minimise the risk of hepatic decompensation.
In the short term, better methods to quantify both infected and integrated hepatocytes in 
biopsies or through serum biomarkers are needed. An in-vivo diagnostic capable of 
visualising the infected liver on medical imaging instruments would be an ideal longterm 
goal. A better understanding of cytolytic clearance of infected cells versus non-cytolytic 
inhibition of viral replication in surviving hepatocytes is needed in humans. Different 
effector functions may be used by T cells or innate effectors (eg, NK, γδ, MAIT cells) 
depending on the quantity or phenotype of newly infected, persistently infected, or 
integrated hepatocytes. The development of less invasive technologies based on fine needle 
aspiration instead of liver biopsies will help to understand these interactions, since they will 
be important to maximise antiviral efficacy and minimise potential toxicity.
Standardisation of immune monitoring in clinical trials
Standardisation of immune monitoring during clinical trials is a monumental but necessary 
task. To improve consistency of immune monitoring between different sites, we propose the 
development of centrally curated and widely available HBV peptide libraries and tetramers. 
Coupled with these would be validated protocols for ELISPOT and flow cytometry staining. 
Such approaches would help promote consistent T-cell monitoring.
Sampling during clinical trials for immunological analysis will be critical to improve and 
advance immune-based therapies. Blood and serum will remain most accessible. Adoption 
of fine needle aspiration should be considered where possible to allow for intrahepatic 
sampling and single cell analyses.116 Timing is key, as innate immune modulators will have 
rapid responses whereas T-cell and B-cell responses will require months of follow-up. 
Comparison of positive responses to the drug or vaccine in patients with chronic HBV 
should not be gauged against baseline responses alone. The magnitude of responses in 
patients with chronic hepatitis B should be compared to phase 1 data in healthy individuals 
or immune responses detected in patients with resolved HBV infection whenever possible. 
This will provide a clearer assessment of immunogenicity in patients with chronic hepatitis 
B. Immune monitoring in early stage drug development should focus on a broader 
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assessment of immunity—eg, high frequency populations, immune profiling, ELISPOT with 
large peptide pools—rather than attempts at fine specificity. Even negative data is useful and 
will promote progress and innovation.
Future of immunotherapy
Just as we are now seeing an expansion of drug targets specific to the virus, expansion of our 
knowledge in key areas related to immune failure and reconstitution will expand the breadth 
of potential immune-based therapies. Identifying the inflection points of immune exhaustion 
for restoration of T-cell and B-cell immunity will improve specificity and reduce toxicity. 
Checkpoint inhibitors that are currently tested in phase 1 trials for their potential to restore 
HBV-specific CD8+ T-cell function offer a promising perspective for HBV immunotherapy. 
However, important questions need to be addressed in future trials about the extent to which 
T cells can be restored, the dose of anti-PD-1 antibodies, the selection of patients likely to 
respond based on biomarkers or disease stage, and the risk of side-effects due to tissue 
damage by restored T cells. In this context, it will also be important to determine the efficacy 
of combination therapies—eg, checkpoint inhibitors with different antiviral therapies or 
therapeutic vaccinations—as has been shown to be effective in preclinical animal models.117 
For therapies targeting innate immunity, separating antiviral efficacy from inflammation 
with pattern recognition receptor agonists could improve their therapeutic index. In addition 
to refining immunotherapy approaches, pushing forward with strategies to engineer antiviral 
immunity hold promise. T-cell receptor and chimeric antigen receptor gene therapies 
circumvent the need for restoration.43,118–122 However, whether long-term engraftment of 
genetically engineered T cells specific for HBV is needed to maintain control of viral spread 
from infected cells that escape elimination, similar to patients with resolved infection, has 
yet to be addressed. Each of these immunotherapeutic strategies should be considered and 
investigated in the context of combination therapy. Rationally pairing antiviral and 
immunotherapeutic drugs based on complementary mechisms of action will hopefully 
ensure potent antiviral effects with elimination of infected hepatocytes and improve HBV 
cure rates.
Coordinated clinical studies to advance HBV cure
While the pharmaceutical industry will develop novel drugs and evaluate them in clinical 
trials, collaborations with clinical scientists outside of industry will be instrumental to the 
success of drug development, by facilitating clinical studies, characterising correlates of 
cure, refining treatment endpoints, and identifying the best patients for clinical trials 
according to the mode of action of the tested drugs.
The timing for initiation of curative regimens will also require careful consideration. There 
is emerging evidence that the HBV disease time-clock commences ticking earlier than 
previously appreciated. This is demonstrated by the finding of integrated HBV DNA in 
infected hepatocytes within a few days of viral infection in vitro123 and in patients during 
the so-called immune tolerant stage of HBV natural history.115 There is also increasing 
evidence that HBV DNA integrations are associated with liver cancer,124 and it remains to 
be determined whether early initiation of treatment would reduce the likelihood of 
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progression to hepatocellular carcinoma by preventing integration, inflammation, and cell 
turnover, and in turn clonal expansion of hepatocytes harbouring integrated sequences.
The identification and characterisation of the virological, immunological, and other host 
correlates or determinants of HBV cure would be of utmost importance to guide the clinical 
development of future curative regimens for patient selection, monitoring of treatment with 
novel biomarkers, and design of clinical trials according to patient characteristics and the 
modes of action of the tested treatments. A repository of serum samples from patients who 
have resolved their HBV infection, including patients with HBsAg loss and those exhibiting 
immune control (anti-HBs), with appropriate matched controls prior to resolution, should be 
established and made accessible to researchers across the globe. This would generate 
considerable statistical power, permitting investigation of serum biomarkers associated with 
HBV resolution, such as HBsAg levels, HBcrAg, and circulating HBV RNA. For some 
samples, matching liver biopsy material and peripheral blood mononuclear cells should be 
obtained, enabling direct comparison of cccDNA (from liver samples) and immune 
responses (from blood samples) with HBV serum markers in patients with chronic hepatitis 
B who lost HBsAg either spontaneously or with currently available treatments.
There is also an urgent need for centralised repositories of HBV-related materials that are 
readily accessible to HBV researchers globally, similar to resources available to colleagues 
in the HIV field. Critical to this will be quality assurance of the samples, and the availability 
of matching clinical data. This repository could be accessed by basic researchers, clinicians, 
biotechnology, and pharmaceutical companies, to facilitate studies and development of new 
drugs. A representative list of reagents required needs to be developed by the HBV 
community and some of the reagents are shown in panel 4.
Conclusions
The time for development and implementation of a safe, affordable, widely available cure 
for chronic hepatitis B for the 257 million people who are affected by HBV globally is now. 
Panel 5 shows the key points that must be urgently prioritised to achieve this goal.
HBV research funding has for too long been woefully inadequate; this must be addressed. 
New research programmes targeting the cccDNA reservoir and stimulating the host immune 
response in a safe and durable manner must be a high priority for researchers, foundations, 
and governments. We support the recent R01 call from the US National Institutes of Health 
for projects on HBV or HIV/HBV immunology, virology, and therapeutics.127 ICE-HBV 
seeks to achieve its goals by fostering collaborative partnerships with researchers (both 
within the HBV field and outside), clinicians, the pharmaceutical industry, and a range of 
stakeholders, including communities affected by chronic hepatitis B; we invite these groups 
to join forces with ICE-HBV in a global effort to discover, develop, test, and implement 
HBV cure strategies, to help ensure that the WHO goal of HBV elimination as a public 
health threat by 2030 is achieved.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Panel 1: Definitions of curative HBV treatment outcomes
• Cure of infection—complete sterilising cure with undetectable HBsAg in 
serum and eradication of HBV DNA including intrahepatic cccDNA and 
integrated HBV DNA31
• Functional cure of HBV infection—sustained, undetectable HBsAg and HBV 
DNA in serum with or without seroconversion to hepatitis B surface antibody 
(anti-HBs), with the persistence of low levels of intrahepatic cccDNA31
• Remission of liver disease—resolution of residual liver injury including 
reversal of fibrosis, prevention of fibrosis progression, remission of disease, 
and reducing risk of hepatocellular carcinoma
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Panel 2: Research priorities and tools for HBV elimination
Priorities
• Develop standardised methods to quantify cccDNA and study mechanisms of 
cccDNA homoeostasis and processes affecting its biogenesis, homoeostasis, 
structure, transcriptional control, and decay
• Define mechanisms determining establishment of HBV infection: characterise 
all steps from cell entry to cccDNA minichromosome formation and 
maintenance
• Improve methods for the study of cccDNA processing and virus-host 
interactions to reveal new targets for therapeutic approaches to clear cccDNA 
by applying state-of-the-art “omics” approaches to increase understanding of 
HBV-host interactions at a genome-wide level
• Develop and validate new serum markers (eg, core related antigens 
[HBcrAgs81], HBV RNA82–84) as reliable bio markers of cccDNA activity in 
the liver. Once markers are identified and characterised, ensure they are 
standardised
• Develop methods to specifically degrade HBV cccDNA
• Develop methods to prevent transcription of cccDNA and integrated HBV 
DNA
• Continue to develop methods to inhibit other key steps of the viral replication 
cycle that could be included in combination strategies to cure the infection
Tool kit
• Develop efficient and convenient in-vitro functional cccDNA systems—eg, 
human hepatocyte-like cells differentiated in vitro from embryonic stem cells 
or induced pluripotent stem cells;primary human hepatocytes and human 
hepatocyte-like cells transplanted into the liver of immune deficient mice for 
expansion after controlled removal of endogenous mouse hepatocytes;68 
robust, specific, and reliable cccDNA reporter cell culture systems
• Develop convenient in-vivo model systems, particularly immunocompetent 
non-human primate and mouse models susceptible to HBV infection—eg, 
non-human primate HBV infection animal models (eg, h-NTCP macaque79); 
humanised mouse models permissive for HBV for immunological studies; 
mouse models fully permissive to HBV infection in murine hepatocytes
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Panel 3: Research priorities and tools for HBV immune control
Priorities
• Conduct clinical studies with existing immune interventions
• Determine the relative contribution of different components of the immune 
system to viral clearance versus viral persistence, immunopathology, and 
treatment response among neonates, children, adolescents, and adults
• Identify the mechanisms of T-cell exhaustion and the extent to which T-cell 
restoration is reversible, durable, and needed for viral control
• Determine the role of B cells in the natural history of disease and how they 
can be effectively monitored for research and clinical trials
• Investigate the impact of the liver microenvironment on the composition and 
function of innate and adaptive cells and identification of biomarkers in the 
blood that best reflect the intrahepatic immune response
• Determine the number of infected hepatocytes in each category of patients 
and the degree of immune-mediated destruction that is required for clearance 
but can still be tolerated before hepatic decompensation occurs
Tool kit
• Develop overlapping peptide libraries to measure virus-specific T-cell 
responses covering the five dominant HBV genotypes
• Develop HLA-tetramer libraries of validated HBV epitopes
• Develop validated flow cytometry and cytokine panels available to 
investigators for immune-profiling
• Develop validated ELISPOT protocols for HBV-specific T and B cells
• Develop validated protocols for stimulation and functional monitoring of 
innate and adaptive immune cells
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Panel 4: Reagent and specimen repositories required to advance HBV cure 
research
• Viral DNA, RNA, and protein standards
• Monoclonal antibodies against HBV proteins
• Replication competent HBV clones of various genotypes and subgenotypes
• Stably transfected cell lines of various genotypes and subgenotypes
• Cell lines susceptible to HBV replication and cell to cell spread
• Mouse and primate models susceptible to HBV infection
• Chemical libraries for studies in experimental models
• Collection of serum and liver biopsy samples from cohort study for research 
purposes
• Peptide libraries for clinical immunology studies
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Panel 5: Immediate and future actions required to achieve HBV cure—the 
ICE-HBV strategy
• INCREASE funding for individual and collaborative cure-related research 
projects by governmental and private funding agencies and philanthropic 
benefactors. Consideration should be given to establishing international 
research consortia, similar to the Martin Delaney Collaboration for HIV 
research managed by the National Institutes of Health in the USA. HBV cure 
research investment strategies should be prioritised in national HBV plans 
globally. We also believe the WHO hepatitis elimination strategy19 should be 
funded in full, with particular focus on delivery of birth dose vaccines and 
substantially increased investments in HBV research. We support recent calls 
from the Hepatitis B Foundation for increased HBV cure research 
funding125,126
• CONCENTRATE on the discovery of interventional strategies that will 
permanently reduce the number of productively infected cells or permanently 
silence the cccDNA in those cells and also stimulate HBV-specific T cells and 
the production of neutralising antibodies that will prevent viral spread to 
uninfected cells, mimicking spontaneous resolution of acute HBV infection
• ESTABLISH repositories of standardised HBV reagents and protocols, 
facilitate access to all researchers across the world, and support the 
development of new animal models of HBV infection
Revill et al. Page 26
Lancet Gastroenterol Hepatol. Author manuscript; available in PMC 2019 September 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Search strategy and selection criteria
• ICE-HBV has facilitated scientific discussions within and between working 
groups on virology, immunology, and innovative tools with input from clinical 
advisors, to identify gaps in HBV cure research and perform the research 
needed to address these. Together these groups form the ICE-HBV scientific 
working group, which met in person in April, 2017, September, 2017, and 
April, 2018, and worked online via Zoom and email to draft this position 
paper. They produced a gap analysis of HBV cure research that served as a 
basis for developing the scientific roadmap for HBV cure. ICE-HBV has 
gathered key stakeholders from around the world to provide input on the 
scientific roadmap. Two consultations were organised in person in Sao Paulo 
and Melbourne. 152 stakeholders from 21 countries and five continents were 
consulted.
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Figure 1: The hepatitis B virus replication cycle
Following viral entry via binding of the preS1 domain of the large envelope protein to the 
sodium-taurocholate co-transporting polypeptide (NTCP) receptor8 on the hepatocyte 
plasma membrane, the viral and cellular membranes fuse to release the nucleocapsid, which 
is transported into the cell nucleus.The nucleocapsid then disassembles to release its cargo of 
partially double-stranded genomic viral DNA. The host DNA repair machinery9 converts the 
incoming DNA to covalently closed circular DNA (cccDNA) molecules that are packaged 
into chromatin-like minichromosomes by histone and non-histone proteins,10,11 whereupon 
it acts as the HBV transcriptional template and long-lived reservoir in the hepatocyte 
nucleus.10 The 3∙2 kb HBV genome is organised into four overlapping but frame-shifted 
open-reading frames encoding the core protein (HBcAg, nucleocapsid); polymerase (P); the 
precore protein, which is processed to secreted hepatitis B e antigen (HBeAg);12 hepatitis B 
surface antigens (HBsAg, consisting of the large, medium, and small envelope proteins); and 
the X protein (HBx). A number of virus-encoded promoter and enhancer elements promote 
transcription of five major mRNAs, namely pregenomic (pgRNA, also the core mRNA), 
precore mRNA, preS1 and preS2/S mRNA, and HBx mRNA, which are translated into the 
aforementioned seven viral proteins. The pgRNA is encapsidated with P and reverse 
transcribed into DNA. Following viral DNA synthesis mature nucleocapsids are either 
packaged with envelope proteins to be exported as infectious virions, or recycled back to the 
nucleus for cccDNA replenishment. DSL-DNA=double-stranded linear DNA. RC-
DNA=relaxed circular DNA.
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Figure 2: Current and future HBV virological and immunological targets that will be necessary 
for treatment and cure of chronic hepatitis B
Adapted from reference 39. CpAMs/CAMs=core protein allosteric modulators/capsid 
assembly modulators. CAR =chimeric antigen receptor. cccDNA=covalently closed circular 
DNA. IL=interleukin. IFN-α=interferon-α. KC=Kupffer cell. NK=natural killer cell. 
NKT=natural killer T cell. pDC=plasmocytoid dendritic cell. RC DNA=relaxed circular 
DNA.
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Figure 3: Mechanisms of CD8+ T-cell failure and potential targets for curative 
immunotherapeutic approaches in the setting of chronic hepatitis B
HBsAg=hepatitis B surface antigen. IL=interleukin. MDSC=myeloid-derived suppressor 
cells. NK=natural killer. TCR=T-cell receptor. TGF=transforming growth factor.
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